Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 5Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Healthy Participants 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour 1Neoplasm Metastasis 1Moderate Hepatic Impairment 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Fallopian Tube Neoplasms 1Chondrosarcoma 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1Advanced Cancer 1

Interventions

Rosuvastatin Calcium 5capivasertib 2Digoxin 2sotorasib 1ibrutinib 1Midazolam 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Healthy Participants × capivasertib × Clear all
NCT07241065 2026-04-15

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

AstraZeneca

Phase 1 Recruiting
42 enrolled

Healthy Participants

NCT07088913 2026-03-03

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

AstraZeneca

Phase 1 Completed
20 enrolled

Healthy Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡